| Bioactivity | ERG245 is a BCAT1 inhibitor that enhances oxidative phosphorylation (OXPHOS) in CD8+ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8+ T cells. ERG245, in combination with Pembrolizumab (anti-PD-1, HY-P9902A), promotes tumor regression. ERG245 can be used in research related to immuno-oncology[1]. |
| Formula | C17H15BrO3 |
| Molar Mass | 347.20 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lodi F, et al. BCAT1 inhibition affects CD8+ T cell activation, exhaustion, and tumoral immunity by altering iron homeostasis[J]. bioRxiv, 2023: 2023.02. 25.530034. |